|
|
Physical Assessment - A Certificate Training Workshop for Pharmacy Practitioners
As pharmacists expand their scope of practice under
new legislation (SB493), physical assessment is a key
skill necessary for advanced practice. This 21 hour
course will prepare the pharmacist to obtain a
history and perform a basic physical examination
that will enable them to assess and monitor drug
therapy. The course will employ written materials,
videos, lectures, demonstrations and hands on
practice and feedback
Objectives for Pharmacists
At the conclusion of the course the p... |
|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
New Guidelines and Novel Treatments for PAH: Taking a Forward-Looking Data Dive Into the Pool of Emerging Therapies
Target Audience
This educational activity has been designed to meet the needs of cardiologists, pulmonologists, rheumatologists, and other physicians, including those in primary care and internal medicine, as well as physician assistants, nurse practitioners, and other healthcare providers who may be involved in managing care for patients with pulmonary arterial hypertension (PAH).
Program Overview
Discoveries about the pathogenesis of pulmonary arterial hypertension (PAH) revealed key mo... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology and family practice. Other members of the care team may also participate.
Program Overview
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subt... |
|
|
Biosimilars in Osteoporosis: Highlights from the ASBMR
Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.
Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternat... |
|